Mirati Therapeutics price target lowered to $57 from $62 at Oppenheimer
Oppenheimer analyst Leah Rush Cann lowered his price target for Mirati Therapeutics to $57 from $62 to account for higher shares outstanding. The analyst reiterates an Outperform rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.